Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

Joining forces in San Francisco
;

Explore our recent stories to see what drives us

17 January 2020

Exploring potential exciting partnerships at the J.P. Morgan Healthcare Conference

A team of Grünenthal’s executives attended the J.P. Morgan Healthcare Conference in San Francisco in January 2020. It’s the world’s biggest healthcare investment symposium – and a chance to discuss partnerships that can help us achieve Grünenthal’s vision of a world free of pain.

“Grünenthal is constantly exploring new R&D partnerships and attractive growth opportunities.”

Gabriel Baertschi,

CEO Grünenthal

The annual J.P. Morgan Healthcare Conference brings together stakeholders from around the world to share information and explore opportunities to advance the development of medicines together. The event took place for the 38th time, attracting more than 9,000 attendees from almost 500 private and public companies, including industry leaders as well as emerging fast-growth companies, innovative technology creators and members of the investment community. If you’re in the healthcare industry, it’s the place to be.
 

The high-calibre Grünenthal team participated in this year’s conference in San Francisco, where they shared insights into the company’s product portfolio, innovation pipeline and current partnerships. Grünenthal has pursued a consistent growth path in recent years and expanded its portfolio by a series of acquisitions with a total value of more than $ 1.3 billion since 2016. Eager to continue this journey by either acquiring established brands for the treatment of pain or entering into research partnerships to co-develop innovative medicines, the team discussed potential collaborations with partners who share the company’s passion for creating innovative pain medicines to improve quality of life for patients.

Grünenthal is an attractive partner for organisations seeking to develop breakthrough treatments because of its combination of an agile mid-size structure with end-to-end capabilities. Privately owned, we are planning for the long term and independent of quarterly fluctuations. Grünenthal is known for its expertise in pain R&D, however, its partners also value its high-quality products and state-of-the-art production facilities. Grünenthal offers a unique combination of characteristics, with the scale and expertise of a large pharma company, as well as the speed and flexibility of a small biotech. That’s why Grünenthal’s team received a lot of interest during the J.P. Morgan Healthcare Conference – and is excited about exploring these opportunities to join forces and move closer towards its vision of a world free of pain.

“We’re committed to open collaborations that create life-changing medicines for patients.”

Jan Adams,

CSO Grünenthal

Share this story: